Agenus (AGEN) Stock Rating Lowered by BidaskClub

BidaskClub lowered shares of Agenus (NASDAQ:AGEN) from a sell rating to a strong sell rating in a research note published on Saturday.

A number of other analysts have also recently commented on AGEN. Zacks Investment Research cut Agenus from a hold rating to a sell rating in a research report on Tuesday, March 20th. ValuEngine cut Agenus from a sell rating to a strong sell rating in a research report on Friday, December 29th. Two analysts have rated the stock with a sell rating, two have assigned a hold rating and two have assigned a buy rating to the company’s stock. Agenus presently has an average rating of Hold and an average price target of $5.81.

How to Become a New Pot Stock Millionaire

Agenus stock opened at $4.46 on Friday. The company has a debt-to-equity ratio of -1.88, a current ratio of 1.30 and a quick ratio of 1.30. Agenus has a one year low of $3.20 and a one year high of $6.19.

Agenus (NASDAQ:AGEN) last posted its quarterly earnings data on Thursday, March 15th. The biotechnology company reported ($0.35) EPS for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.07). The company had revenue of $8.30 million during the quarter, compared to the consensus estimate of $5.30 million. Agenus’s revenue was up 48.2% on a year-over-year basis. equities analysts expect that Agenus will post -1.52 EPS for the current year.

Institutional investors and hedge funds have recently modified their holdings of the business. MetLife Investment Advisors LLC purchased a new stake in Agenus in the fourth quarter worth about $124,000. Raymond James & Associates purchased a new stake in Agenus in the fourth quarter worth about $130,000. Cubist Systematic Strategies LLC purchased a new stake in Agenus in the third quarter worth about $134,000. North Star Asset Management Inc. purchased a new stake in Agenus in the fourth quarter worth about $222,000. Finally, Highbridge Capital Management LLC increased its position in Agenus by 242.8% in the third quarter. Highbridge Capital Management LLC now owns 56,642 shares of the biotechnology company’s stock worth $249,000 after buying an additional 40,118 shares in the last quarter. Institutional investors and hedge funds own 36.46% of the company’s stock.

WARNING: “Agenus (AGEN) Stock Rating Lowered by BidaskClub” was published by Ticker Report and is owned by of Ticker Report. If you are viewing this news story on another domain, it was illegally stolen and republished in violation of US and international copyright & trademark laws. The original version of this news story can be accessed at https://www.tickerreport.com/banking-finance/3340819/agenus-agen-stock-rating-lowered-by-bidaskclub.html.

Agenus Company Profile

Agenus Inc (Agenus) is an immuno-oncology (I-O) company. The Company focuses on the discovery and development of therapies that engage the body’s immune system to fight cancer. It is developing a I-O portfolio driven by platforms and programs, such as antibody discovery platforms, including Retrocyte Display, SECANT yeast display and phage display technologies designed to produce human antibodies; antibody candidate programs, including checkpoint modulator (CPM) programs; vaccine programs, including Prophage, AutoSynVax and PhosPhoSynVax, and saponin-based vaccine adjuvants, principally QS-21 Stimulon adjuvant (QS-21 Stimulon).

Receive News & Ratings for Agenus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agenus and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Zacks: MAM Software Group  Given $8.50 Consensus Target Price by Analysts
Zacks: MAM Software Group Given $8.50 Consensus Target Price by Analysts
Advanced Disposal  Receives Consensus Rating of “Hold” from Analysts
Advanced Disposal Receives Consensus Rating of “Hold” from Analysts
Herc Holdings Inc.  Receives Average Recommendation of “Hold” from Analysts
Herc Holdings Inc. Receives Average Recommendation of “Hold” from Analysts
Freshpet  vs. General Mills  Head to Head Analysis
Freshpet vs. General Mills Head to Head Analysis
Critical Survey: Qurate Retail Group  versus Its Peers
Critical Survey: Qurate Retail Group versus Its Peers
Financial Survey: Telia  versus Its Rivals
Financial Survey: Telia versus Its Rivals


© 2006-2018 Ticker Report. Google+.